AOD-9604 Pipeline and Next-Gen: FDA Status, Safety, and What Comes Next

What Is AOD-9604 and Why Does It Matter?

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone, with a tyrosine-to-tyrosine substitution engineered at position 182 to preserve lipolytic activity while eliminating growth-promoting and diabetogenic effects. Preclinical work by Heffernan et al. demonstrated that this fragment stimulates lipolysis and inhibits lipogenesis in obese mice without altering IGF-1 levels or inducing glucose intolerance 1.

The peptide gained attention because full-length hGH, while lipolytic, carries risks of insulin resistance, fluid retention, and acromegalic side effects. AOD-9604 was designed to decouple the fat-loss signal from those adverse metabolic consequences. Metabolic Pharmaceuticals Ltd, based in Melbourne, Australia, developed the compound through Phase II trials before the program stalled in 2007.

Interest in AOD-9604 has persisted in anti-aging and body-composition optimization circles despite the lack of regulatory progress. The peptide is now available primarily through 503A compounding pharmacies in the United States, prescribed off-label by clinicians who rely on the early preclinical safety profile. That gap between clinical availability and regulatory endorsement is the central tension surrounding AOD-9604 today.

Regulatory History: From Australian Biotech to Clinical Dead End

Metabolic Pharmaceuticals initiated human trials of AOD-9604 in the early 2000s. The compound's regulatory journey is short and instructive, because the program never advanced past mid-stage development.

A Phase IIb trial enrolled approximately 536 obese adults and tested an oral formulation of AOD-9604 at multiple doses against placebo over 24 weeks. The trial did not meet its primary endpoint of statistically significant weight loss compared to placebo. Metabolic Pharmaceuticals disclosed these results in September 2007, and the company's share price collapsed. No subsequent sponsor has filed an IND with the FDA for AOD-9604 in the injectable or oral form.

The FDA's Drugs@FDA database contains no entry for AOD-9604. No Biologics License Application (BLA) or NDA appears in the Orange Book. The compound is also absent from the FDA's list of bulk drug substances nominated for evaluation under Section 503B of the Federal Food, Drug, and Cosmetic Act. This means 503B outsourcing facilities cannot distribute AOD-9604; only patient-specific prescriptions through 503A pharmacies remain a legal pathway 2.

In Australia, the Therapeutic Goods Administration (TGA) granted AOD-9604 GRAS (Generally Recognized as Safe) status strictly for use as a food ingredient, not as a therapeutic drug. This GRAS classification, often cited in marketing materials, does not constitute therapeutic approval and does not transfer to the FDA's regulatory framework.

The Pipeline: Is Anyone Developing AOD-9604?

No. As of May 2026, there are zero active INDs, zero registered clinical trials on ClinicalTrials.gov for AOD-9604, and no publicly disclosed preclinical programs from any pharmaceutical company.

The original intellectual property held by Metabolic Pharmaceuticals has lapsed or been restructured. Calzada Ltd, which acquired Metabolic Pharmaceuticals' assets, pivoted away from obesity peptides entirely. No major pharmaceutical or biotech company has announced plans to resurrect AOD-9604 development.

Several factors explain why the pipeline is empty. First, the Phase IIb failure removed the most compelling evidence pathway. A sponsor seeking to develop AOD-9604 today would need to start essentially from scratch with dose-finding studies, new toxicology packages, and a Phase II/III program likely costing $80-120 million. Second, the competitive environment has transformed since 2007. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% for placebo 3. Tirzepatide 15 mg produced 22.5% weight loss in SURMOUNT-1 (N=2,539) at 72 weeks 4. Any sponsor considering AOD-9604 would need to demonstrate efficacy competitive with these approved agents, a standard the Phase IIb data could not approach.

Third, the FDA's regulatory bar for obesity drugs has increased. The 2023 FDA guidance on developing products for weight management requires sponsors to show durable weight loss of at least 5% greater than placebo with statistical significance, along with improvements in cardiometabolic risk factors 5. AOD-9604's oral formulation failed to demonstrate even this threshold.

Compounding Access: How Patients Currently Obtain AOD-9604

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product for an individual patient based on a valid prescription from a licensed prescriber 2. AOD-9604 is available through this pathway because it is not an FDA-approved product and is not on the FDA's "do not compound" list.

Patients typically receive AOD-9604 as a subcutaneous injectable, reconstituted from lyophilized powder. Common dosing protocols range from 250 mcg to 500 mcg administered once daily, though no FDA-approved labeling exists to standardize these recommendations. Prescribing clinicians rely on the Heffernan et al. preclinical data, the Phase I/II safety data from the Metabolic Pharmaceuticals program, and clinical experience 1.

The legal framework here is specific and narrow. The prescription must be patient-specific. The pharmacy must hold a valid state license. The compound cannot be copies of commercially available drug products. Because AOD-9604 has no commercially available equivalent, it satisfies this criterion. The FDA has periodically increased scrutiny of compounding pharmacies distributing peptides. In 2023, the agency issued warning letters to multiple compounding pharmacies related to peptide products, though none specifically targeted AOD-9604. The agency's ongoing review of bulk drug substances under the 503B pathway could change the accessibility picture, but no formal action against AOD-9604 compounding has been taken.

Safety Profile: What the Evidence Actually Shows

The safety data for AOD-9604 is limited but notable for what it does not show. In the Phase I and Phase IIb trials, no drug-related serious adverse events were reported. The peptide did not increase IGF-1 levels, did not cause glucose intolerance, and did not produce the fluid retention associated with full-length hGH.

Heffernan et al. confirmed in preclinical models that the 176-191 fragment retains lipolytic activity without the growth-promoting or hyperglycemic effects of intact growth hormone 1. A subsequent study by Ng et al. showed that chronic administration of AOD-9604 in obese Zucker rats reduced body fat without affecting lean mass, food intake, or fasting glucose 6.

Dr. Frank Ng, one of the original Monash University researchers, stated in published interviews that "AOD-9604 has a safety profile comparable to placebo in all human studies conducted to date." This is an accurate characterization of the available data, but it is also a characterization bounded by small sample sizes and short follow-up periods. The Phase IIb trial followed patients for only 24 weeks, and total human exposure across all trials is estimated at fewer than 900 subjects.

Post-market surveillance data does not exist in any formal sense because AOD-9604 is not an approved product. The FDA's Sentinel system, MedWatch, and FAERS (FDA Adverse Event Reporting System) contain no structured signal for AOD-9604. The World Anti-Doping Agency (WADA) has prohibited AOD-9604 under category S2 (peptide hormones, growth factors, and related substances) since 2004 7, which limits its use in competitive athletics but does not constitute a safety finding.

The absence of reported harms is not evidence of safety in the way that a completed Phase III program with long-term extension data provides. Clinicians prescribing AOD-9604 through compounding pharmacies should communicate this distinction to patients clearly.

How AOD-9604 Compares to FDA-Approved Obesity Treatments

The comparison is straightforward and one-sided. FDA-approved agents have strong Phase III data; AOD-9604 does not.

Semaglutide 2.4 mg (Wegovy) demonstrated 14.9% placebo-subtracted weight loss at 68 weeks and received FDA approval in June 2021 based on the STEP clinical program involving over 4,500 patients 3. The SELECT trial (N=17,604) subsequently showed a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo 8. Tirzepatide (Zepbound) produced up to 22.5% weight loss in SURMOUNT-1 and received FDA approval for chronic weight management in November 2023 4.

AOD-9604's Phase IIb trial did not achieve statistically significant weight loss over placebo at any tested dose. The oral formulation tested in that trial may have suffered from poor bioavailability, a problem common to peptide-based oral drugs. Whether a subcutaneous formulation at optimized doses could produce clinically meaningful weight loss is unknown because no such trial has been conducted.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities 9. AOD-9604 is not mentioned in this guideline.

Next-Generation Peptides: What Could Replace or Succeed AOD-9604?

The next-generation obesity pipeline has moved decisively toward incretin-based therapies rather than GH-derived peptides.

Oral semaglutide 50 mg (Rybelsus formulation optimization) produced 15.1% weight loss in the OASIS-1 trial (N=667) at 68 weeks 10. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, produced 24.2% weight loss at 48 weeks in a Phase II trial (N=338) 11. Survodutide, an oxyntomodulin analogue targeting GLP-1 and glucagon receptors, produced 18.7% weight loss at 46 weeks in Phase II (N=387) 12.

These agents have pharmaceutical sponsors with resources to fund Phase III programs, established regulatory pathways, and mechanisms of action validated by approved predecessors. AOD-9604 has none of these advantages.

Other peptide research areas include myostatin inhibitors (bimagrumab), amylin analogues (cagrilintide, being co-developed with semaglutide as CagriSema), and melanocortin-4 receptor agonists (setmelanotide for monogenic obesity). None of these are structurally or mechanistically related to AOD-9604.

The realistic assessment is that AOD-9604 occupies a clinical niche sustained by compounding access and clinician experience rather than by an active development pipeline. Unless a sponsor emerges willing to invest in a new IND and Phase II/III program, the compound will remain in this regulatory gray zone indefinitely.

What Would It Take to Get AOD-9604 FDA-Approved?

A hypothetical path to approval would require a sponsor to complete several steps. First, filing an IND supported by current Good Manufacturing Practice (cGMP) chemistry, manufacturing, and controls (CMC) data, along with updated preclinical toxicology studies conducted under Good Laboratory Practice (GLP). Second, completing dose-ranging Phase II studies using a subcutaneous formulation (the oral route having failed). Third, conducting at least two adequately powered Phase III trials with a primary endpoint of percent body weight change at 52-68 weeks. Fourth, submitting an NDA with a complete safety database of at least 1,500 patients exposed for 6 months and 500 for 12 months, per ICH E1 guidelines.

The estimated cost would be $100-150 million over 5-7 years. No current sponsor has the financial incentive to pursue this path when GLP-1 agonists already dominate the market and pipeline. The only plausible scenario that could revive interest would be the discovery of a unique mechanism of action or therapeutic application for AOD-9604, such as localized fat reduction or cartilage repair, that GLP-1 agents cannot replicate. Some preliminary in-vitro data has suggested chondroprotective effects, but this remains speculative and far from clinical validation.

Patients and clinicians considering AOD-9604 should understand this regulatory reality: the compound is legally accessible but clinically unvalidated by modern evidentiary standards, and no change in that status is expected in the near or medium term.